-transparent.png){kind=logo}
A heterologous enzyme immunoassay (EIA) was developed to quantify puromycin aminonucleoside (PA). This double antibody assay was based on the use of anti-puromycin (PU) antibody and used beta-D-galactosidase-labeled PA conjugate prepared via N-(m-maleimidobenzoyloxy)succinimide. The standard curve of the assay ranged from 1 ng to 30 ng, and the lower limit of detection was 22.7 nM (1 ng/tube). The EIA was found to be approximately 20 times more sensitive than the homologous EIA for PA with anti-PA antibody and PA-beta-D-galactosidase conjugate. The heterologous EIA was free from interference by any purine or pyrimidine analogs and drug levels were easily determined in rat tissue following i.v. administration at a dose of 15 mg/kg. The sensitivity and specificity of the EIA should provide a valuable new tool for use in pharmacokinetic and toxicity studies of PA.
K Fujiwara, and
S Ono, and
H Fujinaka, and
T Kitagawa
March 1986,
Cancer research,
K Fujiwara, and
S Ono, and
H Fujinaka, and
T Kitagawa
October 1981,
Journal of pharmacobio-dynamics,
K Fujiwara, and
S Ono, and
H Fujinaka, and
T Kitagawa
April 1983,
Cancer treatment reports,
K Fujiwara, and
S Ono, and
H Fujinaka, and
T Kitagawa
February 1980,
The Journal of clinical endocrinology and metabolism,
K Fujiwara, and
S Ono, and
H Fujinaka, and
T Kitagawa
January 1985,
Cancer chemotherapy and pharmacology,
K Fujiwara, and
S Ono, and
H Fujinaka, and
T Kitagawa
December 1978,
Immunopharmacology,
K Fujiwara, and
S Ono, and
H Fujinaka, and
T Kitagawa
November 1985,
Cancer research,
K Fujiwara, and
S Ono, and
H Fujinaka, and
T Kitagawa
June 1981,
Biochemical pharmacology,
K Fujiwara, and
S Ono, and
H Fujinaka, and
T Kitagawa
October 1979,
Journal of biochemistry,
K Fujiwara, and
S Ono, and
H Fujinaka, and
T Kitagawa
February 1981,
Immunopharmacology,
